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Abstract
Sepsis is a systemic inflammatory response to infection, leading to multiorgan injury and 
mortality. Kallistatin is an endogenous protein expressed in the liver and tissues relevant 
to cardiovascular function. Kallistatin levels are markedly reduced in patients with sepsis 
and liver disease and in lipopolysaccharide (LPS)-induced septic mice. Kallistatin admin-
istration attenuates inflammation, multiorgan damage, and lethality in septic mice with 
LPS treatment, group A streptococcal, or polymicrobial infection. Importantly, kallistatin 
treatment not only prevents but also reverses organ injury and lethality in septic mice. 
Kallistatin decreases sepsis-induced inflammatory responses and tissue damage by modu-
lating differential signaling pathways, including: (1) stimulating endothelial nitric oxide 
(eNOS) and sirtuin 1 (SIRT) synthesis, and NO formation; (2) increasing suppressor of cyto-
kine signaling-3 (SOCS3) expression; (3) antagonizing tumor necrosis factor-α (TNF-α) and 
high mobility group box 1 (HMGB1)-mediated oxidative stress and inflammatory gene 
expression; and (4) displaying bactericidal effects by stimulating superoxide formation. 
Therefore, kallistatin's multifactorial activities provide effective protection during septic 
shock in animal models. As kallistatin displays no apparent cytotoxicity, kallistatin therapy 
may provide a promising approach for the treatment of sepsis in humans.
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1. Introduction
Sepsis is a major contributor to the morbidity and mortality of intensive care patients and a 
leading cause of death worldwide [1, 2]. Sepsis is a systemic inflammatory response to infec-
tion that can lead to multiorgan dysfunction and is mediated by both early (tumor necrosis 
factor-α, TNF-α) and late (high mobility group box 1, HMGB1) inflammatory  cytokines [2, 
3]. Although the underlying pathophysiology of sepsis has not been completely  elucidated, 
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TNF-α and HMGB1 upregulation is known to play a critical role in the inflammatory 
response [4–6]. Moreover, suppressor of cytokine signaling-3 (SOCS3), a feedback  inhibitor of 
lipopolysaccharide (LPS)-induced inflammation, has been shown to be a key player in inhib-
iting nuclear factor (NF)-κB–mediated pro-inflammatory cytokine production [7–9]. Anti-
inflammatory strategies have been investigated with favorable effects in animal models of 
sepsis but with marginal results in humans [10]. Consequently, clinical trials for sepsis have 
been referred to as the “graveyard for pharmaceutical companies” [10]. Because  numerous 
signaling cascades are triggered during septic shock, selective blocking of inflammatory 
mediators is not sufficient to arrest this process. Therefore, the development of novel strate-
gies is vital to the effective treatment of sepsis patients.
Kallistatin was first identified in human plasma as a tissue kallikrein-binding protein (KBP) 
and a new serine proteinase inhibitor (serpin) [11–13]. Kallistatin modulates a wide spectrum 
of biological activities independent of tissue kallikrein [14–20]. Kallistatin is mainly expressed 
in the liver but is also present in the heart, kidney, and blood vessel [21–23]. Kallistatin pro-
tein contains two structural elements: an active site and a heparin-binding domain [24–26]. 
The active site of kallistatin is necessary for complex formation with tissue kallikrein and 
thus inhibition of tissue kallikrein activity and bioavailability [13, 27]. Kallistatin's heparin-
binding domain, however, is essential for antagonizing signaling pathways mediated by 
vascular endothelial growth factor (VEGF), TNF-α, HMGB1, and transforming growth  factor 
(TGF)-β [16, 20, 28, 29]. Kallistatin levels are markedly reduced in hypertensive or normo-
tensive rodents with cardiac and renal injury or streptozotocin-induced diabetes [11, 18, 
30–32]. Circulatory kallistatin levels are also diminished in patients with liver disease, sep-
tic  syndrome, diabetic retinopathy, severe pneumonia, inflammatory bowel disease, obesity, 
prostate, and colon cancer [33–40]. Kallistatin administration by gene or protein delivery pro-
tects against the pathogenesis of hypertension, heart and kidney damage, arthritis, influenza 
virus infection, tumor growth, and metastasis in animal models [15–19, 41–46]. Conversely, 
depletion of endogenous kallistatin by neutralizing antibody injection exacerbates cardio-
vascular and renal injury in hypertensive rats [47]. These findings indicate that kallistatin 
modulates a wide spectrum of biological activities, such as blood pressure, inflammation, 
multiorgan injury, and cancer.
2. Kallistatin via its structural elements regulates differential  
signaling pathways
Kallistatin through its two functional domains modulates numerous signaling pathways and 
biological activities. Kallistatin's active site is crucial for: (1) complex formation with tissue 
kallikrein and inhibiting tissue kallikrein activity and bioavailability [13, 27]; (2) increasing 
eNOS and SIRT1 expression and activation, leading to elevated NO formation [28]; (3) stimu-
lating SOCS3 expression [48]; and (4) interacting with a tyrosine kinase [28, 48]. Kallistatin 
via its heparin-binding domain interacts with cell surface heparan sulfate proteoglycans, 
thereby antagonizing the following biological effects: (1) VEGF-mediated angiogenesis and 
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vascular permeability [16, 20]; (2) TNF-α–induced NF-κB activation, inflammation, oxidative 
stress, and apoptosis [20]; (3) HMGB1-induced inflammatory gene expression and oxidative 
stress [29]; (4) TGF-β–induced endothelial-mesenchymal transition (EndMT), and epithelial- 
mesenchymal transition (EMT) [28]; (5) Wnt-mediated cancer cell proliferation, migration, 
invasion, and autophagy [42, 44]; and (6) EGF-induced cancer cell migration and invasion 
(unpublished results). Thus, kallistatin, with its multifactorial activities, regulates a wide 
spectrum of  biological processes, such as angiogenesis, inflammation, oxidative stress, apop-
tosis, fibrosis, and cancer development.
3. Depleted kallistatin expression and levels in organ damage and sepsis
Kallistatin is a member of the serpin family, which also includes α1-antitrypsin and 
α1-antichymotrypsisn [21]. In contrast to α1-antitrypsin, kallistatin is a negative acute-phase 
protein, as kallistatin expression in rat liver is rapidly downregulated within 24 h after 
lipopolysaccharide (LPS)-induced endotoxemia [31]. Kallistatin levels are depleted in ani-
mal models with hypertension, diabetes, cardiovascular, and renal damage [11, 18, 29–31]. 
Circulatory kallistatin levels are markedly reduced in patients with septic syndrome, liver 
disease, diabetic retinopathy, inflammatory bowel disease, and severe pneumonia [33, 34, 
36–38]. LPS (endotoxin) from Gram-negative bacteria, or peptidoglycan (PepG) and lipotei-
choic acid (LTA) from Gram-positive bacteria, are capable of inducing TNF-α synthesis and 
reactive oxygen species (ROS) formation [49–54]. TNF-α stimulates ROS information in endo-
thelial cells and endothelial progenitor cells [17, 43, 55, 56]. Kallistatin expression and levels 
are negatively regulated by H2O2 through JNK-dependent FOXO1 activation in endothelial cells [57]. Like ROS, TNF-α dramatically suppresses kallistatin expression in endothelial cells 
(Figure 1A). Therefore, kallistatin levels are depleted by the activation of the TNF-α–ROS 
signaling pathway during septic shock (Figure 1B).
Figure 1. (A) TNF-α inhibits kallistatin expression in endothelial cells. TNF-α (10 ng/ml) significantly decreases kallistatin 
expression in endothelial cells. n = 3, *P < 0.05 vs. control groups. (B) LPS/PepG exposure leads to TNF-α synthesis and 
inhibition of kallistatin expression through a ROS-JNK signaling pathway.
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4. Kallistatin is a potent anti-inflammatory agent
Sepsis is a systemic inflammation in response to bacterial infection. Exogenous kallistatin 
attenuates inflammation and multiorgan damage in animals with cardiovascular and renal 
disorders [14, 17–20, 41]. For example, kallistatin gene delivery significantly reduces inflam-
matory responses and joint swelling in arthritic rats [19]. Kallistatin administration also 
suppresses inflammatory cell infiltration and prevents complement factor C5a-induced 
paw edema and vascular leakage in mice [20]. Local delivery of the kallistatin gene into rat 
heart enhances cardiac performance and attenuates inflammatory cell infiltration after acute 
 myocardial ischemia/reperfusion (I/R) [41]. In salt-induced hypertensive rats, kallistatin 
 therapy attenuates vascular and renal damage and reduces oxidative stress and inflammation 
[17, 18], while depletion of endogenous kallistatin augments organ injury and accentuates 
oxidative stress, inflammation, and fibrosis [47].
Kallistatin suppresses inflammatory responses by modulating differential signaling  pathways. 
Kallistatin's active site is responsible for upregulating eNOS and SIRT1 expression, and thus 
increasing NO production [28]. NO, in turn, blocks TNF-α–induced ROS formation by inhib-
iting NADPH oxidase activity and NF-κB activation [58, 59]. Kallistatin via its active site 
induces the expression of SOCS3, a negative regulator of inflammation [48], thereby inhibit-
ing LPS-induced TNF-α production in cultured macrophages [48, 60]. Moreover, kallistatin 
via its heparin-binding site antagonizes TNF-α–induced oxidative stress, NF-κB activation 
and inflammatory gene expression in vitro [20]. Likewise, kallistatin blocks HMGB1-mediated 
synthesis of inflammatory genes in endothelial cells [29]. Moreover, kallistatin ameliorates 
inflammation by blocking VEGF-induced endothelial cell permeability [16, 20]. Thus, kal-
listatin via its two structural domains exerts anti-inflammatory actions by: (1) stimulating 
eNOS and SIRT1 synthesis and NO formation; (2) increasing SOCS3 expression; (3) antago-
nizing TNF-α– and HMGB1-mediated inflammatory gene expression and oxidative stress; 
and (4) blocking VEGF-induced vascular permeability. Together, these findings indicate that 
kallistatin protects against organ damage by inhibiting inflammatory responses through 
 multiple mechanisms.
5. Kallistatin attenuates organ damage and mortality in septic  
animal models
In Gram-negative infections, the cell wall component LPS (endotoxin) is the main  initiator 
of the cascade of cellular reactions that lead to circulatory failure and organ injury [61]. 
Staphylococcus aureus is one of the most common Gram-positive bacteria isolated from 
patients with sepsis [61–63]. Gram-positive bacteria contain two major cell wall components, 
PepG and LTA, which cause sepsis and multiple organ injury in the absence of LPS [49–53]. 
A human kallistatin gene polymorphism is correlated with a decreased risk of developing 
acute kidney injury in patients with septic shock [64]. Kallistatin treatment exerts  beneficial 
effects in Gram-negative and Gram-positive bacteremia, as well as “mixed”  polymicrobial 
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 infection [29, 35, 48, 65]. Transgenic mice expressing kallistatin are highly resistant to 
 mortality induced by LPS [66]. Moreover, kallistatin gene transfer reduces mortality, bacte-
rial counts, and inflammatory cell numbers, as well as skin and liver damage, in a mouse 
model of streptococcal infection [65]. Kallistatin treatment in septic mice with polymicrobial 
infection attenuates lethality, peritoneal bacterial counts, renal injury and inflammation, and 
splenic apoptosis [29]. The protective effects of kallistatin in the kidney occurred in conjunc-
tion with reduced expression of TNF-α and HMGB1 and increased eNOS synthesis and NO 
levels [29]. NO inhibits oxidative organ damage by inactivating NAD(P)H oxidase activity 
[59]. Furthermore, delayed kallistatin administration after the onset of sepsis attenuates mor-
tality, kidney and liver injury in mouse models of polymicrobial sepsis and endotoxemia [48]. 
Kallistatin treatment inhibits systemic inflammation by reducing circulatory levels of TNF-α 
and HMGB1, and dramatically upregulating SOCS3 expression in the kidney and lung [48]. 
Kallistatin delivery improves mortality, attenuates acute lung damage in LPS-induced septic 
mice, and inhibits ROS-mediated inflammation and apoptosis in cultured lung epithelial cells 
[35]. These findings indicate that kallistatin administration significantly enhances survival 
and protects against multiorgan damage during sepsis.
6. Kallistatin enhances bacterial killing by elevated oxidative stress
Oxidative stress has been shown to have beneficial effects with bacterial killing activity in 
inflammatory disorders [67, 68]. Human kallistatin treatment significantly enhances bacte-
rial clearance and antimicrobial activity in group A streptococcus-infected mice by increas-
ing superoxide production in immune cells [65]. Likewise, kallistatin administration leads to 
more than 10-fold decrease of bacterial counts in the peritoneal fluid of mice with polymiro-
bial sepsis [29]. The bactericidal activity of kallistatin is most likely attributed to elevated ROS 
formation in peritoneal neutrophils [61]. Kallistatin also enhances immune cell viability and 
reduces their apoptosis [65]. Kallistatin through its active site increases SOCS3 expression in 
macrophages and SIRT1 synthesis in endothelial cells, but the effects are blocked by genis-
tein [28]. Genistein also abolishes kallistatin's stimulation on endogenous H2O2 formation in vascular smooth muscle cells (unpublished results). These combined findings implicate a role 
of kallistatin's active site in enhancing ROS formation by interaction with a cell surface tyro-
sine kinase. Thus, kallistatin has a double-edged role in oxidative stress, depending on the 
pathological conditions. In addition to inhibiting oxidative stress and multiorgan damage, 
kallistatin is capable of exerting potent bactericidal activity by stimulating ROS formation in 
immune cells of animals with bacterial infection.
7. Signaling mechanisms mediated by kallistatin in sepsis
LPS (endotoxin) derived from Gram-negative bacteria, or PepG and LTA from Gram-positive 
bacteria, can lead to multiorgan injury and lethality by inducing the synthesis of TNF-α 
and HMGB1, thus elevating ROS formation [49–54]. TNF-α activates pro-inflammatory 
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 transcription factor NF-κB and the expression of inflammatory genes, such as ICAM-1 and 
VCAM-1. Kallistatin via its active site stimulates eNOS and SIRT1 expression and activation 
and increases NO formation in endothelial cells; NO in turn inhibits ROS formation [28, 59]. 
Kallistatin's active site is also crucial for increasing SOCS3 expression, leading to inhibition of 
LPS-induced TNF-α synthesis [48, 60]. Kallistatin via its heparin-binding domain blocks TNF-
α– and HMGB1-induced NF-κB activation, inflammatory gene expression, and ROS forma-
tion [20, 29]. However, kallistatin's active site is involved in superoxide formation in immune 
cells, leading to a bacterial killing effect [65]. The signaling pathways mediated by kallistatin 
in the protection against sepsis are shown in Figure 2.
8. Therapeutic implications of kallistatin
Sepsis is a systemic inflammatory response to infection. Kallistatin is an effective anti- 
inflammatory agent by triggering multiple signaling cascades in protection against septic 
shock. Reduction of plasma kallistatin levels is observed in patients with sepsis syndrome and 
is associated with severity of community-acquired pneumonia [33, 36]. Therefore,  circulating 
kallistatin levels may serve as a biomarker for patients with severe sepsis and septic shock. 
Although the beneficial properties of kallistatin treatment in sepsis have been shown in  animal 
studies, they still have yet to be confirmed in humans. Therapeutic application of  kallistatin 
may provide a new approach for the treatment of sepsis and septic shock in humans.
Figure 2. Signaling pathways mediated by kallistatin in sepsis. Kallistatin via its heparin-binding domain blocks 
TNF-α– and HMGB1-induced NF-κB activation, inflammatory gene expression, and ROS formation. Kallistatin via its 
active site stimulates eNOS, SIRT1 and SOCS3 expression, and NO formation, leading to inhibition of oxidative stress. 
Kallistatin increases ROS formation in immune cells. Kallistatin protects against organ injury and lethality during sepsis 
by modulating these differential signaling cascades.
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9. Concluding remarks
Kallistatin levels are markedly reduced in septic shock and inflammatory disease. Kallistatin 
administration exerts beneficial effects during septic shock induced by Gram-negative  bacteremia, 
Gram-positive bacteremia, or polymicrobial infection. Kallistatin possesses potent anti-inflam-
matory activities. Kallistatin via its two structural elements ameliorates inflammatory responses 
by regulating differential signaling cascades. Kallistatin's active site is  crucial for stimulating 
eNOS, SIRT1, and SOCS3 expression and/or activation. Kallistatin via the  heparin-binding site 
antagonizes both early (TNF-α) and late (HMGB1) cytokine-induced  oxidative stress and inflam-
matory gene synthesis. Interestingly, kallistatin has a double-edged role in oxidative stress. In 
addition to suppressing oxidative stress, kallistatin exerts a marked bactericidal effect by stim-
ulating ROS production in immune cells of mice with microbial infection. Kallistatin with its 
pleiotropic activities is an effective therapeutic agent in tissue injury and consequences of septic 
shock.
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